Encouraging efficiency in pharmaceutical discovery and manufacturing, Microsaic’s Chief Technologist Dr. Richard Moseley discusses chip-based technologies and miniaturisation of mass spectrometry.
The current challenges faced by the pharmaceutical industry are nothing new – high costs and failure rates, diminishing R&D pipelines, regulatory approval hurdles, global healthcare concerns, and geopolitical influences to name a few.
Founded in 2001, Microsaic Systems plc (LON:MSYS) is a high technology company which develops point-of-need mass spectrometers, designed to improve the efficiency of chemical and biological workflows.